We are live on ! Find out more
CASC

Cascadian Therapeutics, Inc.
CASC

Delisted

CASC was delisted on the 8th of March, 2018.

Back to rankings

78 hedge funds and large institutions have $168M invested in Cascadian Therapeutics, Inc. in 2017 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 5

165% more capital invested

Capital invested by funds: $63.3M → $168M (+$105M)

150% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 10

37% more funds holding

Funds holding: 57 → 78 (+21)

Holders
78
Holders Change
+21
Holders Change %
+36.84%
% of All Funds
1.94%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
30
Increased
25
Reduced
10
Closed
5
Calls
$741K
Puts
–
Net Calls
+$741K
Net Calls Change
+$202K

Top Buyers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
+$30.6M
2
BG
Baupost Group
Massachusetts
+$19.1M
3
RG
Redmile Group
California
+$17.1M
4
EC
EcoR1 Capital
California
+$12.6M
5
A
Abingworth
United Kingdom
+$3.89M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$2.29M
2
FO
FT Options
Illinois
-$145K
3
First Eagle Investment Management
First Eagle Investment Management
New York
-$108K
4
VKH
Virtu KCG Holdings
New York
-$97.7K
5
EWM
Edge Wealth Management
New York
-$85K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$37.5M +$30.6M +7,272,909 +406%
BG
2
Baupost Group
Massachusetts
$36.1M +$19.1M +4,554,413 +109%
RG
3
Redmile Group
California
$16.9M +$17.1M +4,072,424 New
BI
4
BVF Inc
California
$13M – – –
EC
5
EcoR1 Capital
California
$12.4M +$12.6M +3,000,000 New
ACA
6
Avoro Capital Advisors
New York
$7.54M +$3.78M +900,000 +98%
Vanguard Group
7
Vanguard Group
Pennsylvania
$5.89M +$3.22M +766,725 +117%
Franklin Resources
8
Franklin Resources
California
$4.61M – – –
A
9
Abingworth
United Kingdom
$3.83M +$3.89M +925,000 New
QF
10
QVT Financial
New York
$3.31M +$3.36M +800,000 New
AFM
11
Anson Funds Management
Texas
$2.78M +$1.86M +441,643 +193%
SFM
12
Sphera Funds Management
Israel
$2.41M +$2.44M +581,210 New
PC
13
Polar Capital
United Kingdom
$2.28M +$2.31M +550,000 New
SH
14
Sandia Holdings
Connecticut
$2.25M – – –
BlackRock
15
BlackRock
New York
$2.22M +$2.26M +536,611 New
GPP
16
Great Point Partners
Connecticut
$1.56M +$1.59M +377,900 New
Millennium Management
17
Millennium Management
New York
$1.42M +$1.24M +295,215 +626%
Deutsche Bank
18
Deutsche Bank
Germany
$1.22M +$333K +79,100 +37%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$1.05M +$577K +137,350 +119%
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$934K +$748K +177,849 +372%
Goldman Sachs
21
Goldman Sachs
New York
$849K +$778K +185,081 +921%
DCM
22
DAFNA Capital Management
California
$767K +$779K +185,259 New
OAM
23
Oxford Asset Management
United Kingdom
$671K +$169K +40,117 +33%
SM
24
Sabby Management
Florida
$669K +$680K +161,670 New
FO
25
FT Options
Illinois
$594K -$145K -34,400 -19%
1
2 3 4

CASC Hedge Fund Activity: Q1 2017 in Review

78 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q1 2017, worth a combined $168M — up 165% from $63.3M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new CASC positions and 5 closed out — a net gain of 25 holders — while 25 added to existing stakes and 10 trimmed.

The largest buyer was NEA Management Company, adding an estimated $30.6M. The largest seller was Perceptive Advisors, cutting an estimated $2.29M.

  • 78 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q1 2017, up from 57 in Q4 2016.
  • Funds reported $168M of Cascadian Therapeutics, Inc. stock for Q1 2017, up 165% quarter-over-quarter.
  • 30 funds opened new Cascadian Therapeutics, Inc. positions in Q1 2017 and 5 closed out, a net change of +25 holders.
  • The largest Cascadian Therapeutics, Inc. buyer in Q1 2017 was NEA Management Company, an estimated $30.6M added.
  • The largest Cascadian Therapeutics, Inc. seller in Q1 2017 was Perceptive Advisors, an estimated $2.29M sold.

Based on aggregated 13F filings for Q1 2017.